These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11942173)

  • 1. [Piperacillin-tazobactam in the treatment of severe nosocomial infections].
    Venditti M; Cassone M; Falcone M; Pavoni G; Pistella E; Paris A
    Recenti Prog Med; 2002 Mar; 93(3):200-11. PubMed ID: 11942173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
    Gorschlüter M; Hahn C; Fixson A; Mey U; Ziske C; Molitor E; Horré R; Sauerbruch T; Marklein G; Schmidt-Wolf IG; Glasmacher A
    Support Care Cancer; 2003 Jun; 11(6):362-70. PubMed ID: 12690546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae.
    Akhan S; Coskunkan F; Tansel O; Vahaboglu H
    Scand J Infect Dis; 2001; 33(7):512-5. PubMed ID: 11515761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
    Pillay T; Pillay DG; Adhikari M; Sturm AW
    Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
    Perry CM; Markham A
    Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
    Stearne LE; van Boxtel D; Lemmens N; Goessens WH; Mouton JW; Gyssens IC
    Antimicrob Agents Chemother; 2004 May; 48(5):1688-98. PubMed ID: 15105122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of glycopeptide-resistant enterococci in an oncology unit.
    Bradley SJ
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):203S-212S; discussion 224S-228S. PubMed ID: 11001327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM; Brogden RN
    Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H; Lv Y; Wang D; Xue J; Yan Z
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
    Harris AD; Perencevich E; Roghmann MC; Morris G; Kaye KS; Johnson JA
    Antimicrob Agents Chemother; 2002 Mar; 46(3):854-8. PubMed ID: 11850272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.
    Charbonneau P
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S43-8. PubMed ID: 7962989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drugs: piperacillin/tazobactam].
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):132-3. PubMed ID: 7711129
    [No Abstract]   [Full Text] [Related]  

  • 17. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies.
    Hazel DL; Graham J; Dickinson JP; Newland AC; Kelsey SM
    J Chemother; 1997 Aug; 9(4):267-72. PubMed ID: 9269607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum].
    Vyhnánek F; Faltýn J; Lochmann O
    Rozhl Chir; 2002 Dec; 81(12):617-21. PubMed ID: 12666475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibiotic therapy of secondary nosocomial peritonitis].
    Montravers P
    Presse Med; 1999 May 1-8; 28(17):948-50. PubMed ID: 10360197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.